Even As PBMs Face Reckoning, Formulary Exclusions Rise Again In 2023
Executive Summary
Congressional scrutiny aside, ‘the rebate model remains alive and well’ as the big three pharmacy benefit managers exclude around 600 drugs each from their formularies.
You may also be interested in...
Biocon Pumps Up For Adalimumab US Debut Amid Payer ‘Steady State’
Biocon is confident of its “four channel strategy” for the upcoming debut of biosimilar Humira in the US and also asserts it’s well positioned to compete when price cuts come into play for Sanofi’s Lantus next year.
Biocon Pumps Up For Adalimumab US Debut Amid Payer ‘Steady State’
Biocon is confident of its “four channel strategy” for the upcoming debut of biosimilar Humira in the US and also asserts it’s well positioned to compete when price cuts come into play for Sanofi’s Lantus next year.
The Next Big PBM Deal? Rumored Cigna-Humana Talks Raise Overlap Question
Vigorous regulatory scrutiny is a given, but opinions vary about how much the companies’ respective PBM businesses present a major antitrust risk.